<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 13, 1999
COCENSYS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-20954 33-0538836
(Commission File No.) (IRS Employer Identification No.)
213 TECHNOLOGY DRIVE
IRVINE, CA 92618
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (949) 753-6100
<PAGE>
ITEM 5. OTHER EVENTS.
On July 13, 1999, CoCensys, Inc. (the "Company") received notification from
the Nasdaq Stock Market that the Company's common stock would be deleted from
the Nasdaq National Market (NMS) effective at the close of business on July 13,
1999. The Company's press release announcing the delisting is included herein as
Exhibit 99.1.
ITEM 7. EXHIBITS.
99.1 Press Release, dated July 14, 1999 entitled "CoCensys Delisted
From Nasdaq National Market."
2.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
COCENSYS, INC.
Dated: July 16, 1999 By: /s/ F. Richard Nichol, Ph.D.
------------------------------------
F. RICHARD NICHOL, PH.D.
CHAIRMAN, PRESIDENT AND CHIEF
EXECUTIVE OFFICER
3.
<PAGE>
INDEX TO EXHIBITS
99.1 Press Release, dated July 14, 1999 entitled "CoCensys Delisted
From Nasdaq National Market."
4.
<PAGE>
Contact: F. Richard Nichol, Ph.D.
CHAIRMAN OF THE BOARD
PRESIDENT & CHIEF EXECUTIVE OFFICER
Donna D. Slade
ASSISTANT DIRECTOR, INVESTOR RELATIONS/PUBLIC RELATIONS
COCENSYS, INC.
949/753-6110
COCENSYS, INC. ANNOUNCES DELISTING FROM NASDAQ NATIONAL MARKET
COMPANY ELIGIBLE TO BE TRADED ON OTC BULLETIN BOARD
IRVINE, CALIFORNIA/PR NEWSWIRE/JULY 14, 1999 - CoCensys, Inc. (Nasdaq: COCN)
announced today that the Company has received notification from the Nasdaq Stock
Market that the Company's common stock has been delisted from the Nasdaq
National Market. The Company's common stock is immediately eligible to trade on
the OTC Bulletin Board.
CoCensys is a biopharmaceutical company that discovers and develops products for
the treatment of neurological and psychiatric disorders. The Company's product
development programs focus on novel small molecule compounds for the treatment
of epilepsy, anxiety, Parkinson's and other neurodegenerative diseases,
neuropathic pain, migraine, insomnia and stroke. CoCensys has development
programs with the Wyeth-Ayerst Laboratories Division of American Home Products
Corporation to develop analogs of naturally-occurring neuroactive compounds,
"epalons," for the treatment of anxiety, with Parke-Davis Pharmaceutical
Division of Warner-Lambert Company to identify and develop subtype-selective
NMDA receptor antagonists for the treatment of a variety of neurological and
psychiatric diseases, and with Senju Pharmaceutical and Parke-Davis for the
exploration of ophthalmic indications of CoCensys' glutamate receptor antagonist
compounds. More information about the Company is available on its web site:
http://www.cocensys.com.
